Carrie B. Lee

Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors

Garrett M. Frampton, Siraj M. Ali, Mark R. Rosenzweig et al. · Cancer Discovery · 2015 · 796 citations · Full text

Medicine, Molecular Genetics, Oncology +16

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

Chen Zhao, Katherine A. Cheng, Zandra E. Walton et al. · Nature · 2012 · 451 citations

Medicine, Genetics, Oncology +10

Cardiac Toxicity After Radiotherapy for Stage III Non–Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy

Kyle Wang, Michael J. Eblan, Allison M. Deal et al. · Journal of Clinical Oncology · 2017 · 427 citations

Medicine, Oncology, Radiation Oncology +17

Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell Types

Matthew D. Wilkerson, Xiaoying Yin, Katherine A. Hoadley et al. · Clinical Cancer Research · 2010 · 295 citations · Full text

Medicine, Bioinformatics, Oncology +17

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

Jonathan D. Schoenfeld, Anita Giobbie‐Hurder, Srinika Ranasinghe et al. · The Lancet Oncology · 2022 · 232 citations · Full text

Medicine, Oncology, Radiation Oncology +14